Using GLP-1 drugs for PCOS fertility prep sparks cautious debate over safety and long-term effects

Women with polycystic ovary syndrome are increasingly using GLP-1 receptor agonists like Ozempic and Mounjaro to manage weight and insulin resistance as part of fertility preparation, raising questions about safety, timing, and long-term outcomes.

GLP-1 drugs such as Ozempic, Wegovy and Mounjaro are being used by some women with polycystic ovary syndrome and insulin resistance as part of a fertility prep strategy, not as a direct fertility treatment. The appeal is straightforward: these medicines can curb appetite, improve blood sugar control and help with weight loss, which may in turn reduce excess androgen production and allow ovulation to resume. But the central limitation remains unchanged. These drugs are not designed for people who are actively trying to conceive and are not recommended during pregnancy.

That distinction matters because the medications are increasingly being discussed as a way to improve the metabolic problems that often sit behind irregular cycles. Drugs.com notes that GLP-1 receptor agonists are not FDA-approved for PCOS, but may help with weight and insulin resistance, two of the most common hurdles in the condition. A guide published by glp-1.com says tirzepatide, sold as Mounjaro, is also being used off-label for women with PCOS because of its effects on appetite, blood sugar and fat loss.

The fertility question, though, is more complicated than whether the drugs can help someone lose weight. A multicentre study published in BMJ Open found that inadvertent early pregnancy exposure to GLP-1 receptor agonists was not associated with a higher risk of major birth defects. Another study in JAMA Internal Medicine reported similar findings for first-trimester exposure to GLP-1s and other second-line diabetes medicines. Even so, both studies stressed the need for more data, and current prescribing guidance for semaglutide still says to stop the drug at least 2 months before a planned pregnancy.

There is also growing concern about what happens after people stop the medication. A report highlighted by Live Science said newer observational research has linked discontinuation before or early in pregnancy with greater gestational weight gain and higher rates of gestational diabetes, preterm delivery and hypertensive disorders. Those findings do not prove causation, but they do reinforce a practical point: the real goal is not just to lose weight temporarily, but to address the metabolic drivers that affect fertility in the first place.

For women trying to conceive, that usually means building a more durable foundation around blood sugar, nutrition and movement. The article argues that the best use of a GLP-1 may be as a short-term tool in the preparation phase, paired with a broader plan to improve insulin sensitivity and hormone balance so fertility is not dependent on the drug itself. The safest next step, as the prescribing guidance and the research both suggest, is to make any decision about starting, stopping or timing one of these medicines with a physician who can account for the full fertility picture.